SynOx Therapeutics to present two posters at CTOS 2021 virtual Annual Meeting

Axel Mescheder, CMO, to present an update on phase III, registrational trial of emactuzumab for patients suffering with TGCT (TANGENT) Professor David Kerr, FRCP, to present on “Emactuzumab: Target Mediated Drug Disposition” CTOS virtual Annual Meeting 10-13 November 2021 Dublin, Ireland, November 12, 2021: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical…

Read More

About

SynOx Therapeutics Limited is a late-stage clinical biopharmaceutical company registered in Ireland.

In November 2020, SynOx acquired from Roche an exclusive worldwide licence to emactuzumab, a potentially best-in-class CSF-1R therapeutic antibody.

Emactuzumab has a well-tolerated safety profile and showed remarkable efficacy in patients suffering from diffuse Tenosynovial Giant Cell Tumours (TGCT), a rare disease that causes significant pain and disability. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialisation.